Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

FDA-Approved Medical Devices for Weight Loss and Management

FDA 승인을 받은 체중 감량과 체중관리를 위한 의료기기

  • Yuri Seo (Department of Family Medicine, Chungnam National University Sejong Hospital)
  • 서유리 (세종충남대학교병원 가정의학과)
  • Received : 2023.02.26
  • Accepted : 2023.06.08
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Obesity is a major public health problem worldwide, with several methods having been proposed as a means of weight loss. If diet, exercise, and medication are insufficient, a healthcare professional may suggest weight loss treatments, including bariatric surgery or medical devices. Antiobesity medical devices are an option for patients who do not want to undergo bariatric surgery. Compared with bariatric surgery, medical devices have the advantage of being reversible and easier to operate. The U.S. Food and Drug Administration (FDA) regulates medical devices, including those used for weight loss and weight management. This article provides an overview of the FDA-regulated weight loss and weight management devices.

Keywords

References

  1. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21-33. https://doi.org/10.3810/pgm.2009.11.2074
  2. Afshin A, Forouzanfar MH, Reitsma MB, et al.; GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27. https://doi.org/10.1056/NEJMoa1614362
  3. Yang YS, Han BD, Han K, Jung JH, Son JW; Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr 2022;31:169-77. https://doi.org/10.7570/jomes22024
  4. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019;381:2440-50. https://doi.org/10.1056/NEJMsa1909301
  5. Morino M, Toppino M, Forestieri P, Angrisani L, Allaix ME, Scopinaro N. Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg 2007;246:1002-7; discussion 1007-9. https://doi.org/10.1097/SLA.0b013e31815c404e
  6. Abu Dayyeh BK, Edmundowicz SA, Jonnalagadda S, et al.; ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee. Endoscopic bariatric therapies. Gastrointest Endosc 2015;81:1073-86. https://doi.org/10.1016/j.gie.2015.02.023
  7. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 2017;152:1791-801. https://doi.org/10.1053/j.gastro.2017.01.044
  8. Dixon JB, Eaton LL, Vincent V, Michaelson R. LAP-BAND for BMI 30-40: 5-year health outcomes from the multicenter pivotal study. Int J Obes (Lond) 2016;40:291-8. https://doi.org/10.1038/ijo.2015.156
  9. Michaelson R, Murphy DK, Gross TM, Whitcup SM; LAP-BAND Lower BMI Study Group. LAP-BAND for lower BMI: 2-year results from the multicenter pivotal study. Obesity (Silver Spring) 2013;21:1148-58. https://doi.org/10.1002/oby.20477
  10. Phillips E, Ponce J, Bhoyrul S, et al. Safety and effectiveness of REALIZE adjustable gastric band: 5-year prospective study. Surg Obes Relat Dis 2021;17:956-62. https://doi.org/10.1016/j.soard.2021.01.019
  11. Ikramuddin S, Blackstone RP, Brancatisano A, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA 2014;312:915-22. Erratum in: JAMA 2015;313:95.
  12. Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015;11:874-81. https://doi.org/10.1016/j.soard.2014.12.006
  13. Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond) 2017;41:427-33. https://doi.org/10.1038/ijo.2016.229
  14. Sullivan S, Swain J, Woodman G, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis 2018;14:1876-89. https://doi.org/10.1016/j.soard.2018.09.486
  15. Thompson CC, Abu Dayyeh BK, Kushner R, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol 2017;112:447-57. https://doi.org/10.1038/ajg.2016.500
  16. U.S. Food and Drug Administration. Summary of safety and effectiveness data: TransPyloric Shuttle/TransPyloric Shuttle Delivery Device [Internet]. U.S. Food and Drug Administration. 2019 [cited 2023 May 30]; Available from: https://www.ac-cessdata.fda.gov/cdrh_docs/pdf18/P180024B.pdf
  17. Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet 2021;398:1965-73. Erratum in: Lancet 2021;398:1964. https://doi.org/10.1016/S0140-6736(21)02394-1
  18. Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet 2022;400:441-51. https://doi.org/10.1016/S0140-6736(22)01280-6
  19. Ryan DH, Parkin CG, Longley W, Dixon J, Apovian C, Bode B. Efficacy and safety of an oral device to reduce food intake and promote weight loss. Obes Sci Pract 2017;4:52-61. https://doi.org/10.1002/osp4.139
  20. Greenway FL, Aronne LJ, Raben A, et al. A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity (Silver Spring) 2019;27:205-16. Erratum in: Obesity (Silver Spring) 2019;27:679. Erratum in: Obesity (Silver Spring) 2019;27:1210.
  21. Lap-Band®. The Lap-Band® program gastric banding for weight loss [Internet]. Lap-Band®. 2022 [cited 2023 May 30]; Available from: https://www.lapband.com/
  22. Dixon AF, Dixon JB, O'Brien PE. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 2005;90:813-9. https://doi.org/10.1210/jc.2004-1546
  23. Stefanidis A, Forrest N, Brown WA, et al. An investigation of the neural mechanisms underlying the efficacy of the adjustable gastric band. Surg Obes Relat Dis 2016;12:828-38. https://doi.org/10.1016/j.soard.2015.11.020
  24. O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006;144:625-33. https://doi.org/10.7326/0003-4819-144-9-200605020-00005
  25. Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L. Bariatric surgery survey 2018: similarities and disparities among the 5 IFSO chapters. Obes Surg 2021;31:1937-48. https://doi.org/10.1007/s11695-020-05207-7
  26. Altieri MS, Yang J, Telem DA, et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc 2016;30:1725-32. https://doi.org/10.1007/s00464-015-4402-8
  27. Lazzati A, De Antonio M, Paolino L, et al. Natural history of adjustable gastric banding: lifespan and revisional rate: a nationwide study on administrative data on 53,000 patients. Ann Surg 2017;265:439-45. https://doi.org/10.1097/SLA.0000000000001879
  28. Sudan R, Maciejewski ML, Wilk AR, Nguyen NT, Ponce J, Morton JM. Comparative effectiveness of primary bariatric operations in the United States. Surg Obes Relat Dis 2017;13:826-34. https://doi.org/10.1016/j.soard.2017.01.021
  29. Orbera®. Orbera® managed weight loss system [Internet]. Orbera®. 2016 [cited 2023 May 30]; Available from: https://www.orbera.com/how-it-works
  30. Gomez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity (Silver Spring) 2016;24:1849-53. https://doi.org/10.1002/oby.21555
  31. Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring) 2013;21:1561-70. https://doi.org/10.1002/oby.20414
  32. Cho JH, Bilal M, Kim MC, Cohen J; Study Group for Endoscopic Bariatric and Metabolic Therapies of the Korean Society of Gastrointestinal Endoscopy. The clinical and metabolic effects of intragastric balloon on morbid obesity and its related comorbidities. Clin Endosc 2021;54:9-16. https://doi.org/10.5946/ce.2020.302
  33. Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al.; ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015;82:425-38.e5. https://doi.org/10.1016/j.gie.2015.03.1964
  34. Chan DL, Cruz JR, Mui WL, Wong SKH, Ng EKW. Outcomes with intra-gastric balloon therapy in BMI <35 non-morbid obesity: 10-year follow-up study of an RCT. Obes Surg 2021;31:781-6.
  35. U.S. Food and Drug Administration. Summary of safety and effectiveness data: Obalon® balloon system [Internet]. U.S. Food and Drug Administration. 2016 [cited 2023 May 30]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf16/ p160001c.pdf
  36. Mion F, Ibrahim M, Marjoux S, et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg 2013;23:730-3. https://doi.org/10.1007/s11695-013-0927-x
  37. U.S. Food and Drug Administration. Summary of safety and effectiveness data: Spatz3 adjustable balloon system [Internet]. U.S. Food and Drug Administration. 2021 [cited 2023 May 30]; Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190012B.pdf
  38. Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 2011;21:1499-507. https://doi.org/10.1007/s11695-011-0424-z
  39. Usuy E, Brooks J. Response rates with the Spatz3 adjustable balloon. Obes Surg 2018;28:1271-6. https://doi.org/10.1007/s11695-017-2994-x
  40. Fittipaldi-Fernandez RJ, Zotarelli-Filho IJ, Diestel CF, et al. Randomized prospective clinical study of Spatz3® adjustable intragastric balloon treatment with a control group: a large-scale Brazilian experiment. Obes Surg 2021;31:787-96. https://doi.org/10.1007/s11695-020-05014-0
  41. Apollo Endosurgery [Internet]. Apollo Endosurgery. 2023 [cited 2023 May 30]; Available from: https://apolloendo.com/patients/apollo-esg
  42. Espinet-Coll E, Nebreda-Duran J, Galvao-Neto M, et al. Suture pattern does not influence outcomes of endoscopic sleeve gastroplasty in obese patients. Endosc Int Open 2020;8:E1349-58. https://doi.org/10.1055/a-1221-9835
  43. Fayad L, Adam A, Schweitzer M, et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc 2019;89:782-8. https://doi.org/10.1016/j.gie.2018.08.030
  44. Li R, Veltzke-Schlieker W, Adler A, et al. Endoscopic sleeve gastroplasty (ESG) for high-risk patients, high body mass index (>50 kg/m2) patients, and contraindication to abdominal surgery. Obes Surg 2021;31:3400-9. https://doi.org/10.1007/s11695-021-05446-2
  45. Sharaiha RZ, Hajifathalian K, Kumar R, et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol 2021;19:1051-7.e2. https://doi.org/10.1016/j.cgh.2020.09.055
  46. U.S. Food and Drug Administration. De novo classification request for sensor monitored alimentary restriction therapy (SMART) device [Internet]. U.S. Food and Drug Administration. 2015 [cited 2023 May 30]; Available from: https://www.ac-cessdata.fda.gov/cdrh_docs/reviews/DEN150033.pdf
  47. McGee TL, Grima MT, Hewson ID, Jones KM, Duke EB, Dixon JB. First Australian experiences with an oral volume restriction device to change eating behaviors and assist with weight loss. Obesity (Silver Spring) 2012;20:126-33. https://doi.org/10.1038/oby.2011.303
  48. Giruzzi N. Plenity (oral superabsorbent hydrogel). Clin Diabetes 2020;38:313-4. https://doi.org/10.2337/cd20-0032